J-Y Pierga1, D Hajage2, T Bachelot3, S Delaloge4, E Brain5, M Campone6, V Diéras7, E Rolland2, L Mignot7, C Mathiot8, F-C Bidard9. 1. Department of Medical Oncology, Institut Curie, Paris; Université Paris Descartes, Paris. Electronic address: jean-yves.pierga@curie.net. 2. Department of Biostatistics, Institut Curie, Paris. 3. Department of Medical Oncology, Centre Léon Bérard, Lyon. 4. Department of Medical Oncology, Institut Gustave Roussy, Villejuif. 5. Department of Medical Oncology, Institut Curie, Hôpital René Huguenin, Saint Cloud. 6. Department of Medical Oncology, Centre René Gauducheau, Saint Herblain. 7. Department of Medical Oncology, Institut Curie, Paris. 8. Hematology laboratory, Institut Curie, Paris, France. 9. Department of Medical Oncology, Institut Curie, Paris; Université Paris Descartes, Paris.
Abstract
BACKGROUND: Circulating tumor cells (CTCs) are a prognostic marker in metastatic breast cancer, but comparisons with serum tumor markers (CA 15-3, carcinoembryonic antigen and lactate dehydrogenase) variations are needed. PATIENTS AND METHODS: CTCs were counted with CellSearch® at baseline, before cycle 2 (C2) and cycle 3 or 4 (C3/4) in 267 metastatic breast cancer patients on first-line chemotherapy with/without targeted therapy. RESULTS: Baseline CTC detection rate was 65% with ≥1 CTC/7.5 ml threshold and 44% with ≥5 CTC/7.5 ml and was independent of subtypes (luminal, triple negative, human epithelial growth factor receptor 2 (HER2)+). CTCs were associated with tumor markers, bone/liver involvement, tumor burden and performance status. CTC detection ≥1 CTC/7.5 ml was a strong prognostic factor for progression-free survival (PFS), P < 0.0001. Threshold of CTC ≥5 was statistically significant for PFS and overall survival (OS), P = 0.03 on multivariate analysis. Among patients with ≥5 CTC/7.5 ml at baseline, 50% had <5 CTC/7.5 ml at C2. Changes were correlated with both PFS and OS (P < 0.0001). All patients receiving anti-HER2 therapy had <5 CTC/7.5 ml after three cycles of treatment. CONCLUSION: This is the largest prospective series validating the prognostic value of CTC independently from serum tumor marker. Elevated CTCs before C2 are an early predictive marker of poor PFS and OS, which could be used to monitor treatment benefit. CTC decrease under treatment seems stronger with targeted therapy.
BACKGROUND: Circulating tumor cells (CTCs) are a prognostic marker in metastatic breast cancer, but comparisons with serum tumor markers (CA 15-3, carcinoembryonic antigen and lactate dehydrogenase) variations are needed. PATIENTS AND METHODS: CTCs were counted with CellSearch® at baseline, before cycle 2 (C2) and cycle 3 or 4 (C3/4) in 267 metastatic breast cancerpatients on first-line chemotherapy with/without targeted therapy. RESULTS: Baseline CTC detection rate was 65% with ≥1 CTC/7.5 ml threshold and 44% with ≥5 CTC/7.5 ml and was independent of subtypes (luminal, triple negative, human epithelial growth factor receptor 2 (HER2)+). CTCs were associated with tumor markers, bone/liver involvement, tumor burden and performance status. CTC detection ≥1 CTC/7.5 ml was a strong prognostic factor for progression-free survival (PFS), P < 0.0001. Threshold of CTC ≥5 was statistically significant for PFS and overall survival (OS), P = 0.03 on multivariate analysis. Among patients with ≥5 CTC/7.5 ml at baseline, 50% had <5 CTC/7.5 ml at C2. Changes were correlated with both PFS and OS (P < 0.0001). All patients receiving anti-HER2 therapy had <5 CTC/7.5 ml after three cycles of treatment. CONCLUSION: This is the largest prospective series validating the prognostic value of CTC independently from serum tumor marker. Elevated CTCs before C2 are an early predictive marker of poor PFS and OS, which could be used to monitor treatment benefit. CTC decrease under treatment seems stronger with targeted therapy.
Authors: Yekaterina B Khotskaya; Benjamin H Beck; Douglas R Hurst; Zhenbo Han; Weiya Xia; Mien-Chie Hung; Danny R Welch Journal: Mol Carcinog Date: 2013-09-02 Impact factor: 4.784
Authors: M Banys-Paluchowski; H Schneck; C Blassl; S Schultz; F Meier-Stiegen; D Niederacher; N Krawczyk; E Ruckhaeberle; T Fehm; H Neubauer Journal: Geburtshilfe Frauenheilkd Date: 2015-03 Impact factor: 2.915
Authors: Daniel L Adams; Diane K Adams; R Katherine Alpaugh; Massimo Cristofanilli; Stuart S Martin; Saranya Chumsri; Cha-Mei Tang; Jeffrey R Marks Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-05-17 Impact factor: 4.254
Authors: María José Serrano; Pedro Sánchez Rovira; I Martínez-Zubiaurre; Miguel Delgado Rodriguez; Mónica Fernández; Jose A Lorente Journal: Exp Ther Med Date: 2012-04-05 Impact factor: 2.447